2026 Lymphocytic colitis indication strategy covering epidemiology, JAK biology, active trials, transactions, unmet need, competition and market attractiveness.

2026 Collagenous gastritis indication strategy covering epidemiology, JAK biology, active trials, transactions, unmet need, competition and market attractiveness.

2026 Eosinophilic gastroenteritis indication strategy covering epidemiology, IL-5 biology, active trials, transactions, unmet need, competition and market…

2026 Gastric antral vascular ectasia indication strategy covering epidemiology, VEGF biology, active trials, transactions, unmet need, competition and market…

2026 Portal hypertensive gastropathy indication strategy covering epidemiology, VEGF biology, active trials, transactions, unmet need, competition and market…

2026 Lean metabolic dysfunction-associated steatotic liver disease indication strategy covering epidemiology, FGF21 biology, active trials, transactions, unmet…

2026 Metabolic dysfunction-associated steatohepatitis indication strategy covering epidemiology, THR-beta biology, active trials, transactions, unmet need,…

2026 Alcohol-associated cirrhosis indication strategy covering epidemiology, TGF-beta biology, active trials, transactions, unmet need, competition and market…

2026 Hepatic encephalopathy indication strategy covering epidemiology, GLUL biology, active trials, transactions, unmet need, competition and market attractiveness.

2026 Acute-on-chronic liver failure indication strategy covering epidemiology, IL-6 biology, active trials, transactions, unmet need, competition and market…

2026 Hereditary hemorrhagic telangiectasia liver disease indication strategy covering epidemiology, ACVRL1 biology, active trials, transactions, unmet need,…

2026 Acute liver failure indication strategy covering epidemiology, HMGB1 biology, active trials, transactions, unmet need, competition and market attractiveness.